drugset / Trial / NCT01667211

Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer

NCT01667211

Phase 2 Unknown 30 enrolled Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

Using albumin-bound paclitaxel and nedaplatin in the advanced or recurrent metastasis cervical cancer, to evaluate the efficacy and toxic reaction.

Timeline

Start
2011-11
Primary completion
2014-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nedaplatin Small molecule 80 mg/m2 Intravenous
Subject Nedaplatin Small molecule 100 mg/m2 Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Subject Paclitaxel Small molecule 200 mg/m2 Intravenous

Indications